Christoph Henkenberens

10PUBLICATIONS
40CO-AUTHORS
Predictive and prognostic markersRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Toxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 20, 2024
A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study.

Ali Janbain, Andrea Farolfi, Armelle Guenegou-Arnoux

|May 14, 2020
Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.

Christoph Henkenberens, Ann-Kathrin Oehus, Thorsten Derlin

|May 01, 2020
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.

Ann-Kathrin Oehus, Stephanie G C Kroeze, Nina-Sophie Schmidt-Hegemann

|Mar 18, 2020
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy.

Marco M E Vogel, Stephanie G C Kroeze, Christoph Henkenberens

|Jan 06, 2019
Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer.

Daniel Walacides, Astrid Meier, Anne Caroline Knöchelmann

|Nov 05, 2018
Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer.

Julia Dreyer, Michael Bremer, Christoph Henkenberens

Pageof 2

Frequent Collaborators

2 joint publications

Marco M E Vogel

2 joint publications

Stephanie Gc Kroeze

2 joint publications

Nina-Sophie Schmidt-Hegemann

2 joint publications

Stephanie E Combs